Edition:
United States

Revance Therapeutics Inc (RVNC.OQ)

RVNC.OQ on NASDAQ Stock Exchange Global Market

34.20USD
3:59pm EST
Change (% chg)

$-1.75 (-4.87%)
Prev Close
$35.95
Open
$35.85
Day's High
$36.55
Day's Low
$34.20
Volume
114,475
Avg. Vol
79,569
52-wk High
$37.20
52-wk Low
$15.95

Chart for

About

Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug... (more)

Overall

Beta: 1.58
Market Cap(Mil.): $1,113.43
Shares Outstanding(Mil.): 30.97
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 185.97 15.71
EPS (TTM): -- -- --
ROI: -- -11.84 31.93
ROE: -- -36.93 16.16

BRIEF-Revance Announces Pricing Of Public Offering Of Common Stock

* REVANCE ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Dec 07 2017

BRIEF-Revance Therapeutics Files For Potential Mixed Shelf Offering ‍​‍​

* REVANCE THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING ‍​‍​ Source text: (http://bit.ly/2nwJNaw) Further company coverage:

Dec 05 2017

BRIEF-Revance Announces Proposed Public Offering Of Common Stock

* REVANCE THERAPEUTICS INC - PROPOSED UNDERWRITTEN PUBLIC OFFERING IN WHICH IT WILL ISSUE AND SELL APPROXIMATELY $175 MILLION OF SHARES OF ITS COMMON STOCK

Dec 05 2017

BRIEF-Revance’s RT002 Meets Primary, Secondary Endpoints In Sakura Phase 3 Trials

* REVANCE’S RT002 MEETS PRIMARY AND ALL SECONDARY ENDPOINTS, ACHIEVES 6-MONTH DURATION IN PIVOTAL SAKURA PHASE 3 TRIALS FOR GLABELLAR LINES

Dec 05 2017

BRIEF-Revance Plans Phase 3 Program For RT002 Injectable To Treat Cervical Dystonia

* REVANCE PLANS PHASE 3 PROGRAM FOR RT002 INJECTABLE TO TREAT CERVICAL DYSTONIA

Nov 29 2017

BRIEF-Revance announces orphan drug designation of RT002 for the treatment of Cervical Dystonia

* Revance announces orphan drug designation of RT002 for the treatment of Cervical Dystonia

Nov 20 2017

BRIEF-Revance Therapeutics reports qtrly net loss per share attributable to common stockholders basic and diluted‍​ $1.01

* Revance Therapeutics Inc - ‍sakura 1 & 2 phase 3 pivotal trials on track to report topline results before year-end 2017​

Nov 02 2017

BRIEF-Revance completes patient enrollment in Phase 2 program for RT002 injectable

* Revance completes patient enrollment in Phase 2 program for RT002 injectable in the management of plantar fasciitis

Oct 18 2017

BRIEF-Revance Q2 ‍loss per share $0.90​

* Revance Therapeutics Inc - ‍reaffirmed its financial guidance provided in January 2017​

Aug 03 2017

BRIEF-Revance Therapeutics updates on phase 2 clinical trial results

* Positive Belmont phase 2 trial results published in dermatologic surgery

Jun 15 2017

Earnings vs. Estimates